H. Razavi

Epidemiology · The Lancet · 2012–2021

A researcher in the Science corpus: 10 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

Whom H. Razavi trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Lavanchy

Who trusts H. Razavi overall

  1. Megan H. Bair-Merritt

Papers from H. Razavi's perspective

Ordered by how strongly the researchers H. Razavi trusts endorse each paper. Same corpus, a different order for every researcher.

  1. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (Obesity Facts)
  2. Of markets and rights: Discourse in the 2008 and 2013 Global Action Plan for the Prevention and Control of Noncommunicable Diseases
  3. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The… (Journal of the American College of Cardiology)
  4. Non-Alcoholic Fatty Liver Disease and Hepatocellular Cancer: A Systematic Review (Clinical Gastroenterology and Hepatology)
  5. Nonalcoholic fatty liver disease. (Revista de Gastroenterología de México)
  6. Nonalcoholic fatty liver disease: a systematic review. (Journal of the American Medical Association (JAMA))
  7. USE OF THE FIB4 INDEX FOR NON-INVASIVE EVALUATION OF FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE (Clinical Gastroenterology and Hepatology)
  8. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. (American Journal of Epidemiology)
  9. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. (Hepatology)
  10. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe (Hepatology)

Their papers